Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the United Kingdom.
Nashita PatelShibani PokrasJane FermaVicky CaseyFil ManuguidKen CulverSebastian BauerPublished in: Future oncology (London, England) (2023)
Aim: Describing the treatment patterns, outcomes by line of treatment (LOT), and healthcare resource utilization (HCRU) in patients with metastatic synovial sarcoma (mSS). Patients & methods: In this descriptive, non-interventional, retrospective cohort study, physicians from five European countries reported on patients with recent pharmacological treatment for mSS. Results: Among 296 patients with mSS, 86.1, 38.9 and 8.4% received 1 LOT (1L), 2 LOTs (2L) and 3+ LOTs (L3+), respectively. Common regimens were doxorubicin/ifosfamide-based (37.4%) for 1L and trabectedin-based for 2L (29.7%). For 1L, median time to next treatment was 13.1 and 6.0 months for living and deceased patients, respectively. Median OS was 22.0, 6.0 and 4.9 months in all patients, 2L and 3L, respectively. HCRU data showed median one inpatient hospital admission, 3 days in hospital and four outpatient visits yearly. Conclusion: This large-scale study documents high unmet needs in patients previously treated for mSS and for more effective therapies.
Keyphrases
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- mental health
- type diabetes
- prognostic factors
- peritoneal dialysis
- metabolic syndrome
- drug delivery
- electronic health record
- machine learning
- combination therapy
- patient reported
- artificial intelligence
- adverse drug
- social media
- replacement therapy